Latest filing published 09 Mar 2026 for SynAct Pharma AB, €13k.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -8.2%Entry SEK 18.40 · Close 09 Oct 2026 SEK 16.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Jeppe Øvli Øvlesen: trading record in brief
Jeppe Øvli Øvlesen (chief executive) discloses dealings in SynAct Pharma AB to Finansinspektionen. Over a trading history stretching from 6 January 2021 to 5 March 2026, the count stands at 2 filings.
The open-market record is one-sided, with 1 purchase worth €13k and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2026, the count stands at 1 purchase and no sales.
The record was last updated on 9 March 2026 with an open-market purchase (€13k) in SynAct Pharma AB. Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.
Companies and markets linked to Jeppe Øvli Øvlesen
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 7,900 shares@ SEK 17.99310.015% mcap100.0% of flowAktieISIN SE0008241491FI:A003W854-1Canonical exit: 3 Jun 2026 (T+90)
- 1,456,263 shares0AktieISIN SE0008241491FI:A001P432-1
2 of 2 declarations